Azura Ophthalmics Ltd. (Azura), a clinical-stage biotechnology company with roots in Israel and Australia that is developing therapies for meibomian gland dysfunction (MGD), has completed a $16 million Series B funding round led by a syndicate of OrbiMed, TPG Biotech and Brandon Capital’s Medical Research Commercialisation Fund with participation from an existing investor Ganot Capital.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
